How Wegovy Stands Out from Other Weight Loss Drugs
Wegovy, made by Novo Nordisk, is semaglutide injected weekly at higher doses (up to 2.4 mg) than Ozempic (also semaglutide, max 2 mg for diabetes). It targets GLP-1 receptors to slow gastric emptying, reduce appetite, and regulate blood sugar, leading to 15-20% average body weight loss in trials—higher than most alternatives.[1]
What Sets Wegovy Apart from Ozempic and Zepbound?
Unlike Ozempic, approved only for type 2 diabetes with off-label weight loss use, Wegovy has FDA approval specifically for chronic weight management in adults with obesity or overweight plus comorbidities. Zepbound (tirzepatide by Eli Lilly) is a dual GLP-1/GIP agonist, achieving slightly higher 20-22% weight loss in head-to-head data, but Wegovy has longer real-world availability and a established supply chain despite shortages.[1][2]
| Drug | Active Ingredient | Approval Focus | Avg. Weight Loss (Trials) | Weekly Dose |
|------|-------------------|---------------|---------------------------|-------------|
| Wegovy | Semaglutide | Weight loss | 15-20% | 2.4 mg |
| Ozempic | Semaglutide | Diabetes | 10-15% (off-label) | 2 mg max |
| Zepbound | Tirzepatide | Weight loss | 20-22% | 15 mg max |
| Saxenda | Liraglutide | Weight loss | 5-10% | Daily |
Why Is Wegovy's Weight Loss More Effective Than Older GLP-1 Drugs?
First-generation GLP-1 drugs like Saxenda (daily liraglutide) or older options such as Qsymia (phentermine-topiramate combo) or Contrave (naltrexone-bupropion) deliver 5-10% loss by focusing on appetite suppression or CNS effects. Wegovy's higher-dose semaglutide sustains GLP-1 mimicry longer, mimicking post-meal fullness better and preserving lean muscle during loss, unlike stimulants that risk rebound gain.[1][3]
What Side Effects Differentiate Wegovy?
Common issues—nausea, vomiting, diarrhea—affect 40-50% initially but fade; they're similar to other GLP-1s but less severe than Zepbound's due to single-hormone action. Rare risks include pancreatitis or thyroid tumors (boxed warning), prompting more monitoring than non-injectables like orlistat, which mainly cause GI upset without hormonal effects.[1]
Can You Switch from Other Drugs to Wegovy?
Patients on older pills like phentermine often transition for better sustained results, but GLP-1 experience (e.g., from Ozempic) eases titration to avoid nausea. Wegovy requires obesity qualification (BMI ≥30 or ≥27 with conditions); it's not for cosmetic use, unlike unregulated supplements.[2]
When Does Wegovy's Patent Protection End?
Novo Nordisk holds patents on semaglutide formulations until 2032 in the US, with challenges from competitors like Hims & Hers pushing compounded versions. Exclusivity blocks generics until then, keeping prices high ($1,300/month without insurance).[4]
Sources
[1] FDA labels: Wegovy, Zepbound
[2] NEJM trial (SURMOUNT-1): nejm.org
[3] STEP trials: newenglandjournalofmedicine.org
[4] DrugPatentWatch: drugpatentwatch.com